After having demonstrated significant effects of CK1-specific inhibitors on established lymphoma cell lines, the mRNA expression levels of CK1δ in primary lymphoid tumor tissue, EBV-immortalized lymphoid cells, and blood cells from healthy donors were compared. The gene discussed is CSNK1A1; the disease is lymphoid neoplasm.